Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) 44.4% HIGHER; announced finalization of the protocol for the Company’s Phase II trial of ANA598 in combination with pegylated interferon-alpha and ribavirin in hepatitis C patients. Allowance of the protocol has been received from the US FDA, and patient dosing is expected to commence within the next several weeks. Also reported a Q2 loss of $0.21, 7 cents better than the analyst estimate of ($0.28).

Synaptics Inc. (Nasdaq: SYNA) 26.9% LOWER; reported Q4 EPS of $0.36, below the consensus of $0.44. Revenues came in at $115.3 million, versus the consensus of $112.1 million. The